AbbVie Inc.

NYSE:ABBV 株式レポート

時価総額：US$365.4b

AbbVie 過去の業績

過去 基準チェック /06

AbbVieの収益は年間平均-21%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間30% 2%割合で 増加しています。

主要情報

-20.99%

収益成長率

-21.03%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率2.00%
株主資本利益率n/a
ネット・マージン5.72%
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings

Apr 30

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.

ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution

Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.

ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns

Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.

ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty

The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.

AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition

AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.

ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality

Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.

ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty

Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality

Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.

ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution

Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution

Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.

ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution

Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections

AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures

AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.

Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025

AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.

Expanding Immunology And Neuroscience Will Reshape Global Healthcare

AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.

Expanding Immunology And Neuroscience Will Reshape Global Healthcare

AbbVie’s consensus price target has been raised from $217.45 to $227.22, as analysts highlight the value added by the extended Rinvoq patent runway, top- and bottom-line beats, pipeline expansion through the Bretisilocin acquisition, and underappreciated royalty streams. Analyst Commentary Bullish analysts cite a substantial extension of Rinvoq’s U.S. patent runway through favorable settlement, delaying generic entry until 2037—4 years beyond prior expectations—and modeling this as adding $11-$24 per share in value.

Expanding Immunology And Neuroscience Will Reshape Global Healthcare

AbbVie's price target was raised to $217.45 as analysts cited the value impact of extended Rinvoq exclusivity from litigation settlement, strong Q2 results, and positive pipeline developments, outweighing near-term Aesthetics headwinds. Analyst Commentary Bullish analysts cite the settlement of litigation regarding generic Rinvoq, extending market exclusivity in the U.S. to 2037 and reducing threats from earlier-than-anticipated generic competition.

収支内訳

AbbVie の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:ABBV 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 2662,8193,59513,9299,473
31 Dec 2561,1604,18613,6449,068
30 Sep 2559,6442,34812,6018,787
30 Jun 2558,3283,72313,2158,568
31 Mar 2557,3674,15513,3468,385
31 Dec 2456,3344,23814,0998,131
30 Sep 2455,5335,08113,9687,755
30 Jun 2455,0005,29813,1937,405
31 Mar 2454,4035,95113,0327,189
31 Dec 2354,3184,82012,4197,038
30 Sep 2355,1386,47112,4536,897
30 Jun 2356,0238,63512,2606,785
31 Mar 2356,7417,53512,2016,661
31 Dec 2258,05411,78214,5846,487
30 Sep 2257,81913,34312,1166,518
30 Jun 2257,34912,56911,9886,551
31 Mar 2256,72512,40711,9436,692
31 Dec 2156,19711,46811,8726,820
30 Sep 2155,1697,46511,0546,829
30 Jun 2153,7296,59910,8606,761
31 Mar 2150,1955,09210,9556,418
31 Dec 2045,8044,5569,8676,003
30 Sep 2040,6507,3249,4295,902
30 Jun 2036,2276,9068,2885,582
31 Mar 2034,0578,3956,7605,467
31 Dec 1933,2667,8426,7635,377
30 Sep 1932,8673,2326,4875,260
30 Jun 1932,6244,0936,7655,273
31 Mar 1932,6475,3336,8735,304
31 Dec 1832,7535,6577,3535,259
30 Sep 1832,1877,5316,9725,242
30 Jun 1830,9466,4196,6235,202
31 Mar 1829,6126,3526,3035,109
31 Dec 1728,2165,2836,2485,007
30 Sep 1727,2736,6155,9584,789
30 Jun 1726,7106,5825,7994,667
31 Mar 1726,2186,2785,8614,562
31 Dec 1625,6385,9235,8374,385
30 Sep 1625,2426,0485,7334,178
30 Jun 1624,7545,6905,7244,472
31 Mar 1623,7775,4485,6464,236
31 Dec 1522,8595,1185,6634,101
30 Sep 1521,9112,7906,0593,978
30 Jun 1520,9862,0646,1783,390

質の高い収益: ABBVには$13.6B } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。

利益率の向上: ABBVの現在の純利益率 (5.7%)は、昨年(7.2%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ABBVの収益は過去 5 年間で年間21%減少しました。

成長の加速: ABBVは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: ABBVは過去 1 年間で収益成長率がマイナス ( -13.5% ) となったため、 Biotechs業界平均 ( 40.2% ) と比較することが困難です。

株主資本利益率

高いROE: ABBVの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/04 12:11
終値2026/05/01 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

AbbVie Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。51

アナリスト機関
David ToungArgus Research Company
Emily FieldBarclays
Luisa HectorBerenberg